Previous close | 325.89 |
Open | 326.89 |
Bid | 325.79 x 800 |
Ask | 520.00 x 800 |
Day's range | 325.10 - 329.14 |
52-week range | 162.04 - 329.14 |
Volume | |
Avg. volume | 955,496 |
Market cap | 74.153B |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | 34.59 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.36 (1.03%) |
Ex-dividend date | 07 Jun 2024 |
1y target est | N/A |
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).
SWORDS, Ireland, May 08, 2024--Trane Technologies (NYSE: TT), a global climate innovator, today announced its participation in the U.S. Department of Energy’s (DOE) Commercial Building Heat Pump Technology Challenge. This new initiative is designed to advance the adoption of cost-effective, next-generation heat pump rooftop units and cut carbon emissions. Heat pump rooftop units can reduce greenhouse gas emissions and energy costs by up to 50% compared with conventional rooftop units using natur
Trane Technologies plc (NYSE:TT), a global climate innovator, today reported diluted earnings per share (EPS) from continuing operations of $1.92 for the first quarter of 2024. Adjusted continuing EPS was $1.94, up 38 percent.